

PARP inhibitors in ovarian cancer

Expert perspectives on current clinical questions

Monday 30 September 2019
13.00–14.30

Salamanca Auditorium
Hall 3, Fira Gran Via
Barcelona, Spain

Welcome and introduction

Dr Ana Oaknin (Chair)

Vall d'Hebron University Hospital, Barcelona, Spain

Exploring the evidence for maintenance therapy in recurrent ovarian cancer

Dr Alexandra Leary

Gustave Roussy Cancer Center, Villejuif, France

Surveillance or maintenance? An interactive discussion

Dr Rebecca Kristeleit

UCL Cancer Institute and UCLH Department of Oncology, London, UK

Applying the evidence: case-based decision making in recurrent ovarian cancer

Dr Ana Oaknin

Vall d'Hebron University Hospital, Barcelona, Spain

Where next? Exploring new frontiers for PARP inhibitors in ovarian cancer

Prof Dr Frederik Marmé

University Hospital Mannheim, Mannheim, Germany

Panel Q&A and close

Dr Ana Oaknin